Regeneron Pharmaceuticals (REGN) Earnings Date & Reports

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

REGN is expected to report earnings to fall 23.28% to $9.26 per share on April 29

Regeneron Pharmaceuticals REGN Stock Earnings Reports

Q1'25

Est.

$9.26

Q4'24

Beat

by $0.80

Q3'24

Beat

by $0.74

Q2'24

Beat

by $0.95

Q1'24

Missed

by $0.64

The last earnings report on February 04 showed earnings per share of $12.07, beating the estimate of $11.27. With 791.95K shares outstanding, the current market capitalization sits at 64.27B.

View a ticker or compare two or three

Compare

REGN